image
Healthcare - Biotechnology - NASDAQ - US
$ 47.26
2.03 %
$ 963 M
Market Cap
-4.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PRAX stock under the worst case scenario is HIDDEN Compared to the current market price of 47.3 USD, Praxis Precision Medicines, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PRAX stock under the base case scenario is HIDDEN Compared to the current market price of 47.3 USD, Praxis Precision Medicines, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PRAX stock under the best case scenario is HIDDEN Compared to the current market price of 47.3 USD, Praxis Precision Medicines, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PRAX

image
$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.0$40.0$40.0$30.0$30.0$20.0$20.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
8.55 M REVENUE
249.53%
-200 M OPERATING INCOME
-58.39%
-183 M NET INCOME
-48.30%
-132 M OPERATING CASH FLOW
-18.55%
-248 M INVESTING CASH FLOW
-637.98%
514 M FINANCING CASH FLOW
459.83%
0 REVENUE
0.00%
-74.7 M OPERATING INCOME
-16.84%
-69.3 M NET INCOME
-18.09%
-53 M OPERATING CASH FLOW
5.55%
-51.1 M INVESTING CASH FLOW
-367.70%
54.3 M FINANCING CASH FLOW
-52.30%
Balance Sheet Praxis Precision Medicines, Inc.
image
Current Assets 404 M
Cash & Short-Term Investments 393 M
Receivables 0
Other Current Assets 11.8 M
Non-Current Assets 78.7 M
Long-Term Investments 77 M
PP&E 1.36 M
Other Non-Current Assets 416 K
81.26 %15.93 %Total Assets$483.1m
Current Liabilities 37.6 M
Accounts Payable 12.5 M
Short-Term Debt 1.26 M
Other Current Liabilities 23.8 M
Non-Current Liabilities 110 K
Long-Term Debt 0
Other Non-Current Liabilities 110 K
33.27 %3.34 %63.10 %Total Liabilities$37.7m
EFFICIENCY
Earnings Waterfall Praxis Precision Medicines, Inc.
image
Revenue 8.55 M
Cost Of Revenue 358 K
Gross Profit 8.2 M
Operating Expenses 209 M
Operating Income -200 M
Other Expenses -17.3 M
Net Income -183 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)9m(358k)8m(209m)(200m)17m(183m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
95.81% GROSS MARGIN
95.81%
-2340.29% OPERATING MARGIN
-2340.29%
-2137.48% NET MARGIN
-2137.48%
-41.04% ROE
-41.04%
-37.84% ROA
-37.84%
-44.80% ROIC
-44.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Praxis Precision Medicines, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)20192019202020202021202120222022202320232024202420252025
Net Income -183 M
Depreciation & Amortization 358 K
Capital Expenditures 0
Stock-Based Compensation 41.4 M
Change in Working Capital 10.9 M
Others 2.63 M
Free Cash Flow -132 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Praxis Precision Medicines, Inc.
image
Wall Street analysts predict an average 1-year price target for PRAX of $123 , with forecasts ranging from a low of $73 to a high of $170 .
PRAX Lowest Price Target Wall Street Target
73 USD 54.46%
PRAX Average Price Target Wall Street Target
123 USD 159.73%
PRAX Highest Price Target Wall Street Target
170 USD 259.71%
Price
Max Price Target
Min Price Target
Average Price Target
1801801601601401401201201001008080606040402020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Praxis Precision Medicines, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.09 M USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 5 days ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis' Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee's entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 1 month ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 2 months ago
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link] Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028 BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025. “We have made substantial progress in advancing our promising late-stage epilepsy portfolio and are firing on all cylinders through this unpredictable time in the industry,” said Marcio Souza, president and chief executive officer of Praxis. globenewswire.com - 2 months ago
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT. globenewswire.com - 2 months ago
Praxis Precision Medicines to Participate in Upcoming April Conferences BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April: globenewswire.com - 3 months ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 8,763 shares of its common stock to four new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 3 months ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 2,000 shares of its common stock and restricted stock unit awards covering an aggregate of 7,288 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 4 months ago
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. seekingalpha.com - 4 months ago
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.94 per share versus the Zacks Consensus Estimate of a loss of $2.96. This compares to loss of $2.97 per share a year ago. zacks.com - 4 months ago
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update. globenewswire.com - 4 months ago
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 4 months ago
8. Profile Summary

Praxis Precision Medicines, Inc. PRAX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 963 M
Dividend Yield 0.00%
Description Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Contact 99 High Street, Boston, MA, 02110 https://www.praxismedicines.com
IPO Date Oct. 16, 2020
Employees 116
Officers Mr. Timothy Edwin Kelly Chief Financial Officer & Treasurer Mr. Marcio Silva De'Souza M.B.A. President, Chief Executive Officer & Director Lauren Mastrocola Vice President of Finance & Principal Accounting Officer Ms. Megan T. Sniecinski Chief Business Officer Ms. Alyssa J. S. Wyant Chief Regulatory & Quality Officer Dr. Steven Petrou B.Sc. (Hons.), Ph.D. Co-Founder & Chief Scientific Officer Mr. Alex Kane Vice President of Investor Relations & Corporate Communications Mr. Alex Nemiroff J.D. General Counsel & Secretary Ms. Kelly McCue Chief People Officer Dr. Karl Hansen Ph.D. Chief Technical Operations Officer